相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial
Jinyi Yuan et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2019)
Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers
Zoltan Magyarics et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects
Paul B. Eckburg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution
Elizabeth A. Lakota et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms
Melroy Tellis et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2019)
CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial
Pierre-Francois Laterre et al.
LANCET INFECTIOUS DISEASES (2019)
Safety and Tolerability of Bacteriophage Therapy for Chronic Rhinosinusitis Due to Staphylococcus aureus
Mian Li Ooi et al.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2019)
Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial
Marcus Y. Chen et al.
LANCET INFECTIOUS DISEASES (2019)
Lefamulin. Comment on: Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270
Despoina Koulenti et al.
MICROORGANISMS (2019)
Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms
Despoina Koulenti et al.
MICROORGANISMS (2019)
Design and Preclinical Development of a Phage Product for the Treatment of Antibiotic-Resistant Staphylococcus aureus Infections
Susan M. Lehman et al.
VIRUSES-BASEL (2019)
Ridinilazole: a novel antimicrobial for Clostridium difficile infection
Jonathan C. Cho et al.
ANNALS OF GASTROENTEROLOGY (2019)
Disarming Staphylococcus aureus from destroying human cells by simultaneously neutralizing six cytotoxins with two human monoclonal antibodies
Harald Rouha et al.
VIRULENCE (2018)
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)
Thomas L. Holland et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In vitro and in vivo activity of contezolid (MRX-I) against Mycobacterium tuberculosis
Carolyn Shoen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile
Tarun Mathur et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects
Alexander G. Vandell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, and Its Water-Soluble Prodrug, DS11960558, against Methicillin-Resistant Staphylococcus aureus
Tarani Kanta Barman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Metabolism, Excretion, and Mass Balance of Solithromycin in Humans
Christopher MacLauchlin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model
Sean M. Stainton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Intrapulmonary Pharmacokinetics of Lascufloxacin in Healthy Adult Volunteers
Hidetoshi Furuie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
An overview of recent advances in duplex DNA recognition by small molecules
Sayantan Bhaduri et al.
BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY (2018)
Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation
Stephanie N. Taylor et al.
CLINICAL INFECTIOUS DISEASES (2018)
Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial
Bruno Francois et al.
INTENSIVE CARE MEDICINE (2018)
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections
David B. Huang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Design and Syntheses of Highly Potent Teixobactin Analogues against Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA), and Vancomycin-Resistant Enterococci (VRE) in Vitro and in Vivo
Anish Parmar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
In Vitro Antibacterial Activity of Teixobactin Derivatives on Clinically Relevant Bacterial Isolates
Estelle J. Ramchuran et al.
FRONTIERS IN MICROBIOLOGY (2018)
An Updated Review of Iclaprim: A Potent and Rapidly Bactericidal Antibiotic for the Treatment of Skin and Skin Structure Infections and Nosocomial Pneumonia Caused by Gram-Positive Including Multidrug-Resistant Bacteria
David B. Huang et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
Iclaprim: a differentiated option for the treatment of skin and skin structure infections
Stephanie Noviello et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)
1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S. pneumoniae (SPN)
Alexander J Lepak et al.
Open Forum Infectious Diseases (2018)
Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects
Keith A. Rodvold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1
David B. Huang et al.
CLINICAL INFECTIOUS DISEASES (2018)
Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models
Catharine C. Bulik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults
Xiang-Qing Yu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Single Ascending Dose Safety, Tolerability, and Pharmacokinetics of KBP-7072, a Novel Third Generation Tetracycline
Bin Zhang et al.
Open Forum Infectious Diseases (2017)
What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles
Karen Bush et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2017)
Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens
Trudy H. Grossman et al.
MSPHERE (2017)
Multiple Ascending Dose Safety, Tolerability, and Pharmacokinetics of KBP-7072, a Novel Third-generation Tetracycline
Fred Yang et al.
Open Forum Infectious Diseases (2017)
A Phase 1 Study in Healthy Subjects to Investigate Safety, Pharmacokinetics, and Effect on Intestinal Flora of Multiple Ascending Doses of DS-2969b, A Novel Oral DNA Gyrase B Inhibitor for The Treatment of Clostridium difficile Infection
Satoshi Inoue et al.
Open Forum Infectious Diseases (2017)
SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii
Daniel V. Zurawski et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a MethionyltRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 Study
Seema U. Nayak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741
David Corbett et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens
David B. Huang et al.
CLINICAL THERAPEUTICS (2017)
MICROBIOLOGICAL ANALYSIS FROM A PHASE II STUDY IN ADULTS EVALUATING SINGLE DOSES OF GEPOTIDACIN (GSK2140944) IN THE TREATMENT OF UNCOMPLICATED UROGENITAL GONORRHOEA CAUSED BY NEISSERIA GONORRHOEAE
N. Scangarella-Oman et al.
SEXUALLY TRANSMITTED INFECTIONS (2017)
Solithromycin: A novel ketolide antibiotic
Michael J. Buege et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2017)
Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
William O'Riordan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Activities and Spectrum of the Novel Fluoroquinolone Lascufloxacin (KRP-AM1977)
Ryuta Kishii et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers
Mohammad Hossain et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
What is new in the management of skin and soft tissue infections in 2016?
Garyphallia Poulakou et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2017)
Single-and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects
Paul B. Eckburg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae
D. J. Farrell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant Comorbidities
B. Hafkin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
The metabolism and disposition of GSK2140944 in healthy human subjects
Kitaw Negash et al.
XENOBIOTICA (2016)
In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens
D. J. Biedenbach et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
The solithromycin journey-It is all in the chemistry
Prabhavathi Fernandes et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia
Thomas M. File et al.
CLINICAL INFECTIOUS DISEASES (2016)
Inhaled Antibiotics for Gram-Negative Respiratory Infections
Eric Wenzler et al.
CLINICAL MICROBIOLOGY REVIEWS (2016)
New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance
Ling-Shan Syue et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
An Independent Evaluation of a Novel Peptide Mimetic, Brilacidin (PMX30063), for Ocular Anti-infective
Regis P. Kowalski et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2016)
Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)
Carlos M. Barrera et al.
LANCET INFECTIOUS DISEASES (2016)
Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
Travis M. Jones et al.
INFECTION AND DRUG RESISTANCE (2016)
Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India
Salil Mehta et al.
PLOS ONE (2016)
Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment
Brian D. Jamieson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Arbekacin Activity against Contemporary Clinical Bacteria Isolated from Patients Hospitalized with Pneumonia
Hello S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Activity of Debio1452, a FabI Inhibitor with Potent Activity against Staphylococcus aureus and Coagulase-Negative Staphylococcus spp., Including Multidrug-Resistant Strains
Robert K. Flamm et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections
Richard Vickers et al.
BMC INFECTIOUS DISEASES (2015)
A new antibiotic kills pathogens without detectable resistance
Losee L. Ling et al.
NATURE (2015)
Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial
Chin Kook Rhee et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2015)
Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice
Brian D. Henry et al.
NATURE BIOTECHNOLOGY (2015)
In Vivo Antibacterial Activity of MRX-I, a New Oxazolidinone
Cong-Ran Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Comparative Mechanistic Studies of Brilacidin, Daptomycin, and the Antimicrobial Peptide LL16
Bruk Mensa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Staphylococcus aureus toxins
Michael Otto
CURRENT OPINION IN MICROBIOLOGY (2014)
New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile
Mikhail F. Gordeev et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Review of nemonoxacin with special focus on clinical development
Hai-hui Huang et al.
Drug Design Development and Therapy (2014)
Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens
Tetsuya Matsumoto
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2014)
Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet
HyeKyung Han et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects
Nachum Kaplan et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics
Nachum Kaplan et al.
JOURNAL OF CHEMOTHERAPY (2013)
Approval and Withdrawal of New Antibiotics and Other Antiinfectives in the U.S., 1980-2009
Kevin Outterson et al.
JOURNAL OF LAW MEDICINE & ETHICS (2013)
New antibiotics for bad bugs: where are we?
Matteo Bassetti et al.
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2013)
Pipeline of Known Chemical Classes of Antibiotics
Cristina d'Urso de Souza Mendes et al.
ANTIBIOTICS-BASEL (2013)
Cethromycin versus Clarithromycin for Community-Acquired Pneumonia: Comparative Efficacy and Safety Outcomes from Two Double-Blinded, Randomized, Parallel-Group, Multicenter, Multinational Noninferiority Studies
Marci L. English et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor
Nachum Kaplan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Comparison of Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Solithromycin (CEM-101) in Healthy Adult Subjects
Keith A. Rodvold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides
J. E. Cornick et al.
MICROBES AND INFECTION (2012)
Staphylococcus aureus Induces Eosinophil Cell Death Mediated by α-hemolysin
Lynne R. Prince et al.
PLOS ONE (2012)
Summary of Pharmacokinetics and Tissue Distribution of a Broad-Spectrum Fluoroquinolone, JNJ-Q2
J. Michael Davenport et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2012)
In Vitro Antimicrobial Activity of Razupenem (SMP-601, PTZ601) against Anaerobic Bacteria
Chau Minh Tran et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
JNJ-Q2, a New Fluoroquinolone with Potent In Vitro Activity against Staphylococcus aureus, Including Methicillin- and Fluoroquinolone-Resistant Strains
David J. Farrell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Pharmacokinetics of Solithromycin (CEM-101) after Single or Multiple Oral Doses and Effects of Food on Single-Dose Bioavailability in Healthy Adult Subjects
J. Gordon Still et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Efficacy of a New Fluoroquinolone, JNJ-Q2, in Murine Models of Staphylococcus aureus and Streptococcus pneumoniae Skin, Respiratory, and Systemic Infections
Jeffrey Fernandez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Efficacy of Human-Simulated Exposures of Tomopenem (Formerly CS-023) in a Murine Model of Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus Infection
Kiyoshi Sugihara et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Antistaphylococcal Activities of the New Fluoroquinolone JNJ-Q2
Brian J. Morrow et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Pharmacodynamics of Razupenem (PZ601) Studied in an In Vitro Pharmacokinetic Model of Infection
Alasdair P. MacGowan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci
Shannon D. Putnam et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
Antibiotics in the clinical pipeline in 2011
Mark S. Butler et al.
JOURNAL OF ANTIBIOTICS (2011)
Cellular Pharmacokinetics of the Novel Biaryloxazolidinone Radezolid in Phagocytic Cells: Studies with Macrophages and Polymorphonuclear Neutrophils
Sandrine Lemaire et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In Vitro Antibacterial Activities of JNJ-Q2, a New Broad-Spectrum Fluoroquinolone
Brian J. Morrow et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae
Hee Soo Park et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates
David J. Farrell et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Type IIA topoisomerase inhibition by a new class of antibacterial agents
Benjamin D. Bax et al.
NATURE (2010)
Iclaprim, a Novel Diaminopyrimidine for the Treatment of Resistant Gram-Positive Infections
Carrie A. Sincak et al.
ANNALS OF PHARMACOTHERAPY (2009)
In Vitro Activity of the Quinolone WCK 771 against Recent US Hospital and Community-Acquired Staphylococcus aureus Pathogens with Various Resistance Types
Sachin S. Bhagwat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Multicenter, Randomized Study of the Efficacy and Safety of Intravenous Iclaprim in Complicated Skin and Skin Structure Infections
D. Krievins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Potency and Bactericidal Activity of Iclaprim against Recent Clinical Gram-Positive Isolates
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Cellular Accumulation and Pharmacodynamic Evaluation of the Intracellular Activity of CEM-101, a Novel Fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in Human THP-1 Macrophages
Sandrine Lemaire et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates
Heather J. Adam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Nemonoxacin Quinolone antibiotic
A. Arjona
DRUGS OF THE FUTURE (2009)
Telithromycin-Associated Hepatotoxicity: Clinical Spectrum and Causality Assessment of 42 Cases
Allen D. Brinker et al.
HEPATOLOGY (2009)
Radezolid (RX-1741), a novel oxazolidinone, accumulates extensively within human macrophages and PMNs and shows activity towards intracellular linezolid-sensitive and linezolid-resistant Staphylococcus aureus
S. Lemaire et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections
Ian A. Critchley et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Update on the treatment of Pseudomonas aeruginosa pneumonia
Ali A. El Solh et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria
Diane M. Citron et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity
Christian Oefner et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model
Urs A. Ochsner et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem
Navita L. Mallalieu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa
Tetsufumi Koga et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections
Francoise Van Bambeke et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model
Yoshitomo Morinaga et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action
H. Laue et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Iclaprim
Stephan A. Kohlhoff et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men
J. Andrews et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor
Hee Soo Park et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers
Takahiro Shibayama et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase
Sachin S. Bhagwat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone
Hee-Soo Park et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem
Y Ueda et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem
T Koga et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae
JH Jorgensen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vitro activity of the new quinolone WCK 771 against staphylococci
MR Jacobs et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models
MV Patel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis
FJ Schmitz et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2002)
Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes
H Aoki et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit
DE Brodersen et al.
CELL (2000)
分享论文
